High Dose of Intravenous Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells (CLV-100) Infusion Displays Better Immunomodulatory Effect among Healthy Volunteers: A Phase 1 Clinical Study

Table 4

Baseline and follow-up clinical assessments among subjects in the HD group.

Parameters	Baseline day 0	Follow-up period				value^a
		Day 2	Day 30	Day 90	Day 180
Routine blood tests
WBC (×10^9/L)						0.69
Hemoglobin (g/dL)						0.04
HCT (%)						0.12
MCV (fl)						0.02
Platelet (×10^9/L)						0.20
Creatinine (μmol/L)						0.50
ESR (mm/hr)						0.13
AST (IU/L)						0.81
ALT (IU/L)						0.77
Albumin (g/L)						0.23
Globulin (g/L)						0.01
A/G ratio						0.01
Total cholesterol (mmol/L)						0.09
HbA1c (%)		—				0.08
FBS (mmol/L)		—				0.20
Insulin (ng/mL)		—				0.14
IGF-1(ng/mL)		—				0.78
DHEAS (μmol/L)		—				0.12
Estradiol (pg/mL)		—				0.15
Progesterone (ng/mL)		—				0.86
Testosterone (ng/mL)		—				0.62
hs-CRP (mg/L)						0.04
IgE (IU/mL)						0.79
Total PSA (ng/mL)		—				0.24
CA125 (U/mL)		—				0.96
CA15.3 (U/mL)		—				0.31
CEA (ng/mL)		—				0.21
CA19.9 (U/mL)		—				0.06
AFP (ng/mL)		—				0.88
Vital signs
SBP (mmHg)						0.16
DBP (mmHg)						0.21
Heart rate (beats/min)						0.39
Lung function tests
FEV1 (L)			—			0.79
FVC (L)			—			0.03
FEV1/FVC (%)			—			0.95
Biomarkers
IL-6 (pg/mL)				—		0.06
IL-10 (pg/mL)				—		0.13
PGE2 (pg/mL)				—		0.19
IL1-RA (pg/mL)				—		0.03
TNF-α (pg/mL)				—		0.67
TGF-β (pg/mL)				—		0.42
VEGF (pg/mL)				—		0.58
HGF (pg/mL)				—		0.58

^aThe Friedman test. Significant value at .